Tidal Therapeutics / Sanofi
Sanofi acquired Tidal in April 2021 for its nanoparticle mRNA platform for in vivo immune-cell reprogramming, including CAR-T applications. This is a historical acquired-platform record; the original preclinical description is not a verified current program stage or an independent active biotech.
Corporate information
- Company entity
- Tidal Therapeutics / Sanofi
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- Historical entityNot verified
- Official corporate reference
- https://www.sanofi.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Sanofi acquired Tidal in April 2021 for its nanoparticle mRNA platform for in vivo immune-cell reprogramming, including CAR-T applications. This is a historical acquired-platform record; the original preclinical description is not a verified current program stage or an independent active biotech.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Tidal Therapeutics / Sanofi — primary program / ownership disclosure
- Official corporate website audit